Education
About Us
Working with TipRanks
Follow Us
StemRIM Inc. (JP:4599)
:4599
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥370.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥18.62B
Enterprise Value¥12.42B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.49
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Debt / Conservative Balance SheetA near-zero debt load materially lowers refinancing and interest-rate risk for a development-stage biotech. This conservative capital structure preserves flexibility to time financings, sustain R&D spending through volatile cycles, and reduces the chance of covenant-driven distress.
Proven Intermittent Cash GenerationHistorical episodes of strong operating cash inflows show the company can generate meaningful cash when milestones or commercial/partner events occur. That demonstrated ability can underpin medium-term funding strategies and indicates upside if similar catalysts reoccur.
Prior Profitable Years And Revenue SpikePast profitability and a large 2023 revenue increase indicate the business model has delivered commercial or partner-driven revenue before. These precedents suggest the company has viable commercialization or collaboration pathways that can be leveraged again.
Bears Say
Zero Revenue And Large Losses (2024–2025)Sustained absence of revenue while costs remain high undermines margin sustainability and forces persistent reliance on external funding. Continued large losses over multiple years increase the risk of dilution, constrain reinvestment capacity, and threaten long-term viability without new income sources.
Inconsistent And Deteriorating Cash FlowVolatile cash generation creates uncertainty around runway and makes planning for multi-year R&D difficult. The recent sustained outflows increase dependence on capital markets or partners, elevating financing risk and the likelihood of frequent dilutive raises if operational performance does not stabilize.
Declining Equity And Negative Returns On EquityEroding equity and repeated negative ROE signal shareholder value dilution from ongoing losses. A shrinking capital base reduces the buffer against future setbacks, limits capacity to absorb R&D setbacks, and increases the company's vulnerability in prolonged development cycles.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥370.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥18.62B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 4 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Dec 10, 2025. The company reported -¥8.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥8.49.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥8.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―